A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population
- PMID: 12116252
- DOI: 10.1002/ajmg.10401
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population
Abstract
Van Buchem disease is an autosomal recessive sclerosing bone dysplasia characterized by skeletal hyperostosis, overgrowth of the mandible, and a liability to entrapment of the seventh and eighth cranial nerves. The genetic determinant maps to chromosome 17q12-q21. We refined the critical interval to the < 1-Mb region between D17S2250 and D17S2253 in 15 affected individuals, all of whom shared a common disease haplotype. Furthermore, we report here the identification of a 52-kb deletion located within the interval and encompassing D17S1789 that is 100% concordant with the disorder. Although the deletion itself does not appear to disrupt the coding region of any known or novel gene(s), the closest flanking genes are MEOX1 on the proximal side, and SOST on the distal side of the deletion. MEOX1 is known to be important for the development of the axial skeleton, whereas the SOST gene is the determinant of sclerosteosis, a disorder that shares many features with van Buchem disease, thus raising the possibility that van Buchem disease results from dysregulation of the expression of one or both of these genes.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
-
A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene.Bone. 2005 Jun;36(6):943-7. doi: 10.1016/j.bone.2005.02.019. Bone. 2005. PMID: 15869924
-
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.J Med Genet. 2002 Feb;39(2):91-7. doi: 10.1136/jmg.39.2.91. J Med Genet. 2002. PMID: 11836356 Free PMC article.
-
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.Cytokine Growth Factor Rev. 2005 Jun;16(3):319-27. doi: 10.1016/j.cytogfr.2005.02.005. Cytokine Growth Factor Rev. 2005. PMID: 15869900 Review.
-
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).Hum Mol Genet. 2001 Mar 1;10(5):537-43. doi: 10.1093/hmg/10.5.537. Hum Mol Genet. 2001. PMID: 11181578
-
Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?J Musculoskelet Neuronal Interact. 2004 Jun;4(2):139-42. J Musculoskelet Neuronal Interact. 2004. PMID: 15615113 Review.
Cited by
-
Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management.Rheumatology (Oxford). 2013 Jun;52(6):968-85. doi: 10.1093/rheumatology/ket007. Epub 2013 Feb 27. Rheumatology (Oxford). 2013. PMID: 23445662 Free PMC article. Review.
-
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.J Exp Med. 2004 Mar 15;199(6):805-14. doi: 10.1084/jem.20031454. J Exp Med. 2004. PMID: 15024046 Free PMC article.
-
Rare and Common Variants in GALNT3 May Affect Bone Mass Independently of Phosphate Metabolism.J Bone Miner Res. 2023 May;38(5):678-691. doi: 10.1002/jbmr.4795. Epub 2023 Mar 13. J Bone Miner Res. 2023. PMID: 36824040 Free PMC article.
-
Sclerostin: current knowledge and future perspectives.Calcif Tissue Int. 2010 Aug;87(2):99-107. doi: 10.1007/s00223-010-9372-1. Epub 2010 May 15. Calcif Tissue Int. 2010. PMID: 20473488 Free PMC article. Review.
-
Regulation of circulating sclerostin levels by sex steroids in women and in men.J Bone Miner Res. 2011 Jan;26(1):27-34. doi: 10.1002/jbmr.128. J Bone Miner Res. 2011. PMID: 20499362 Free PMC article. Clinical Trial.
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous